- $19.98m
- $10.71m
- $57.57m
Aytu Biopharma Inc reports results for the quarter ended in June - Earnings Summary
Brief: Aytu Biopharma Inc Qtrly Total Net Revenue Was $30.7 Million, Up 12%
Aytu Biopharma Inc expected to post a loss of 95 cents a share - Earnings Preview
Aytu Biopharma Inc expected to post a loss of 95 cents a share - Earnings Preview
Brief: Aytu Biopharma Announces Exclusive Deal With Medomie In Israel And Palestinian Authority
Brief: Aytu Biopharma Inc - Announces Submission Of Cotempla Xr-Odt Manufacturing Site Transfer Prior Approval Supplement
Brief: Stonepine Capital Reports 9.99% Passive Stake In Aytu Biopharma Shares
Brief: Nantahala Capital Management Reports 7.2% Stake In Aytu Biopharma As Of May 26
Aytu Biopharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: Aytu Biopharma Inc Reports Q3 Loss Of $1.93 Per Share
Aytu Biopharma Inc expected to post a loss of 63 cents a share - Earnings Preview
Brief: Aytu Biopharma Inc Files For Offering Of Up To 4.9 Million Shares
Brief: Aytu Biopharma Subleases A Portion Of Its Manufacturing Facility
Brief: Aytu Biopharma Announces Approval Of Adzenys Xr-Odt Manufacturing Site Transfer
Brief: Aytu Biopharma Inc Engaged In Discussions With Various Parties Regarding Potential Strategic Transactions And Potential Financing Options
Brief: Aytu Biopharma - Board,Management Decided Some Of Co's Previously Issued Interim Unaudited Consolidated Financial Statements Should No Longer Be Relied Upon
Brief: Aytu Biopharma Inc - QTRLY Basic And Diluted Net Loss Per Common Share $2.15
Aytu Biopharma Inc expected to post a loss of $1.60 a share - Earnings Preview
Brief: Aytu Biopharma Regains Nasdaq Minimum Bid Price Compliance